Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Sell
31
WST Quote, Financials, Valuation and Earnings
Last price:
$228.71
Seasonality move
:
8.24%
Day range:
$225.44 - $230.66
52-week range:
$197.01 - $397.72
Dividend yield:
0.36%
P/E ratio:
34.18x
P/S ratio:
5.83x
P/B ratio:
6.16x
Volume:
2.6M
Avg. volume:
1.4M
1-year change:
-42.24%
Market cap:
$16.5B
Revenue:
$2.9B
EPS (TTM):
$6.69
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$740.9M | $1.73 | -1.46% | -20.5% | $285.01 |
|
BAX
Baxter International
|
$2.7B | $0.53 | -27.96% | 589.09% | $40.04 |
|
BDX
Becton Dickinson &
|
$5.1B | $2.99 | 6.03% | 77.19% | $276.37 |
|
PDEX
Pro-Dex
|
$13.8M | $0.38 | 23.84% | 147.37% | $54.00 |
|
RMD
ResMed
|
$1.3B | $2.31 | 7.21% | 15.65% | $270.09 |
|
TFX
Teleflex
|
$813.2M | $3.88 | -4.16% | 826.82% | $168.21 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$228.68 | $285.01 | $16.5B | 34.18x | $0.21 | 0.36% | 5.83x |
|
BAX
Baxter International
|
$33.19 | $40.04 | $17B | 167.20x | $0.17 | 2.77% | 1.32x |
|
BDX
Becton Dickinson &
|
$230.23 | $276.37 | $66.1B | 38.24x | $1.04 | 1.73% | 3.24x |
|
PDEX
Pro-Dex
|
$48.83 | $54.00 | $159.2M | 24.42x | $0.00 | 0% | 2.73x |
|
RMD
ResMed
|
$219.70 | $270.09 | $32.3B | 25.94x | $0.53 | 0.94% | 6.58x |
|
TFX
Teleflex
|
$141.56 | $168.21 | $6.6B | 99.69x | $0.34 | 0.96% | 2.19x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
7.02% | 1.553 | 0.92% | 1.88x |
|
BAX
Baxter International
|
65.34% | 0.281 | 88.33% | 0.54x |
|
BDX
Becton Dickinson &
|
42.67% | 0.476 | 28.8% | 0.44x |
|
PDEX
Pro-Dex
|
33.99% | 3.333 | 10.75% | 1.35x |
|
RMD
ResMed
|
11.35% | 0.169 | 2% | 1.74x |
|
TFX
Teleflex
|
27.91% | 1.867 | 20.11% | 1.15x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services
|
$273.6M | $169.8M | 16.88% | 18.15% | 21.92% | $85.2M |
|
BAX
Baxter International
|
$959M | -$1M | -3.07% | -8.24% | -15.29% | $351M |
|
BDX
Becton Dickinson &
|
$2.2B | $546M | 3.92% | 6.75% | 8.92% | $588M |
|
PDEX
Pro-Dex
|
$5.1M | $2.7M | 15.21% | 21.59% | 16.61% | -$4.7M |
|
RMD
ResMed
|
$751.3M | $417.2M | 21.74% | 25.56% | 32.54% | $285.2M |
|
TFX
Teleflex
|
$439.9M | $140.8M | 1.13% | 1.57% | -13.59% | $170.4M |
West Pharmaceutical Services vs. Competitors
-
Which has Higher Returns WST or BAX?
Baxter International has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of -18.6%. West Pharmaceutical Services's return on equity of 18.15% beat Baxter International's return on equity of -8.24%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services36.54% $1.78 $2.9B BAXBaxter International34.84% -$1.00 $20.2B -
What do Analysts Say About WST or BAX?
West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 24.63%. On the other hand Baxter International has an analysts' consensus of $40.04 which suggests that it could grow by 20.65%. Given that West Pharmaceutical Services has higher upside potential than Baxter International, analysts believe West Pharmaceutical Services is more attractive than Baxter International.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services8 2 0 BAXBaxter International3 11 1 -
Is WST or BAX More Risky?
West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.847% more volatile than S&P 500. In comparison Baxter International has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.696%.
-
Which is a Better Dividend Stock WST or BAX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.36%. Baxter International offers a yield of 2.77% to investors and pays a quarterly dividend of $0.17 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BAX?
West Pharmaceutical Services quarterly revenues are $748.8M, which are smaller than Baxter International quarterly revenues of $2.8B. West Pharmaceutical Services's net income of $130.1M is higher than Baxter International's net income of -$512M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 34.18x while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.83x versus 1.32x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.83x 34.18x $748.8M $130.1M BAXBaxter International1.32x 167.20x $2.8B -$512M
-
Which has Higher Returns WST or BDX?
Becton Dickinson & has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of 5.86%. West Pharmaceutical Services's return on equity of 18.15% beat Becton Dickinson &'s return on equity of 6.75%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services36.54% $1.78 $2.9B BDXBecton Dickinson &43.25% $1.04 $44B -
What do Analysts Say About WST or BDX?
West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 24.63%. On the other hand Becton Dickinson & has an analysts' consensus of $276.37 which suggests that it could grow by 20.04%. Given that West Pharmaceutical Services has higher upside potential than Becton Dickinson &, analysts believe West Pharmaceutical Services is more attractive than Becton Dickinson &.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services8 2 0 BDXBecton Dickinson &7 4 0 -
Is WST or BDX More Risky?
West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.847% more volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.355, suggesting its less volatile than the S&P 500 by 64.526%.
-
Which is a Better Dividend Stock WST or BDX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.36%. Becton Dickinson & offers a yield of 1.73% to investors and pays a quarterly dividend of $1.04 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BDX?
West Pharmaceutical Services quarterly revenues are $748.8M, which are smaller than Becton Dickinson & quarterly revenues of $5.2B. West Pharmaceutical Services's net income of $130.1M is lower than Becton Dickinson &'s net income of $303M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 34.18x while Becton Dickinson &'s PE ratio is 38.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.83x versus 3.24x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.83x 34.18x $748.8M $130.1M BDXBecton Dickinson &3.24x 38.24x $5.2B $303M
-
Which has Higher Returns WST or PDEX?
Pro-Dex has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of 12.15%. West Pharmaceutical Services's return on equity of 18.15% beat Pro-Dex's return on equity of 21.59%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services36.54% $1.78 $2.9B PDEXPro-Dex30.2% $0.61 $48.2M -
What do Analysts Say About WST or PDEX?
West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 24.63%. On the other hand Pro-Dex has an analysts' consensus of $54.00 which suggests that it could grow by 10.59%. Given that West Pharmaceutical Services has higher upside potential than Pro-Dex, analysts believe West Pharmaceutical Services is more attractive than Pro-Dex.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services8 2 0 PDEXPro-Dex1 0 0 -
Is WST or PDEX More Risky?
West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.847% more volatile than S&P 500. In comparison Pro-Dex has a beta of 0.682, suggesting its less volatile than the S&P 500 by 31.755%.
-
Which is a Better Dividend Stock WST or PDEX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.36%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or PDEX?
West Pharmaceutical Services quarterly revenues are $748.8M, which are larger than Pro-Dex quarterly revenues of $16.8M. West Pharmaceutical Services's net income of $130.1M is higher than Pro-Dex's net income of $2M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 34.18x while Pro-Dex's PE ratio is 24.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.83x versus 2.73x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.83x 34.18x $748.8M $130.1M PDEXPro-Dex2.73x 24.42x $16.8M $2M
-
Which has Higher Returns WST or RMD?
ResMed has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of 26.88%. West Pharmaceutical Services's return on equity of 18.15% beat ResMed's return on equity of 25.56%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services36.54% $1.78 $2.9B RMDResMed58.6% $2.34 $5.9B -
What do Analysts Say About WST or RMD?
West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 24.63%. On the other hand ResMed has an analysts' consensus of $270.09 which suggests that it could grow by 22.94%. Given that West Pharmaceutical Services has higher upside potential than ResMed, analysts believe West Pharmaceutical Services is more attractive than ResMed.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services8 2 0 RMDResMed8 6 1 -
Is WST or RMD More Risky?
West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.847% more volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.
-
Which is a Better Dividend Stock WST or RMD?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.36%. ResMed offers a yield of 0.94% to investors and pays a quarterly dividend of $0.53 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or RMD?
West Pharmaceutical Services quarterly revenues are $748.8M, which are smaller than ResMed quarterly revenues of $1.3B. West Pharmaceutical Services's net income of $130.1M is lower than ResMed's net income of $344.6M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 34.18x while ResMed's PE ratio is 25.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.83x versus 6.58x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.83x 34.18x $748.8M $130.1M RMDResMed6.58x 25.94x $1.3B $344.6M
-
Which has Higher Returns WST or TFX?
Teleflex has a net margin of 17.38% compared to West Pharmaceutical Services's net margin of -17.18%. West Pharmaceutical Services's return on equity of 18.15% beat Teleflex's return on equity of 1.57%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services36.54% $1.78 $2.9B TFXTeleflex55.31% -$2.95 $5.9B -
What do Analysts Say About WST or TFX?
West Pharmaceutical Services has a consensus price target of $285.01, signalling upside risk potential of 24.63%. On the other hand Teleflex has an analysts' consensus of $168.21 which suggests that it could grow by 18.83%. Given that West Pharmaceutical Services has higher upside potential than Teleflex, analysts believe West Pharmaceutical Services is more attractive than Teleflex.
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services8 2 0 TFXTeleflex0 11 0 -
Is WST or TFX More Risky?
West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.847% more volatile than S&P 500. In comparison Teleflex has a beta of 1.211, suggesting its more volatile than the S&P 500 by 21.134%.
-
Which is a Better Dividend Stock WST or TFX?
West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.36%. Teleflex offers a yield of 0.96% to investors and pays a quarterly dividend of $0.34 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or TFX?
West Pharmaceutical Services quarterly revenues are $748.8M, which are smaller than Teleflex quarterly revenues of $795.4M. West Pharmaceutical Services's net income of $130.1M is higher than Teleflex's net income of -$136.7M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 34.18x while Teleflex's PE ratio is 99.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.83x versus 2.19x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services5.83x 34.18x $748.8M $130.1M TFXTeleflex2.19x 99.69x $795.4M -$136.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
